报告题目：Development of novel therapeutics in oncology
Peter Lobie obtained a B.Med.Sci. (Distinction) and MBBS (Medicine First Class Honours) in 1992 from the University of Queensland in Australia. He was awarded the highest accolade from the University in the form of a University Medal. His postdoctoral work was undertaken at the Karolinska Institute in Sweden where he also obtained his doctoral degree (PhD). He has consecutively held faculty positions in Sweden, Singapore and New Zealand. He was also New Zealand’s first chair of Breast Cancer funded by the Breast Cancer Research Trust. He was Professor and Senior Principal Investigator at the Cancer Science Institute of Singapore before being appointed co-Director of the Centre for Precision Medicine and Healthcare at the Tsinghua-Berkeley Shenzhen Institute.
Peter Lobie is author of over 180 publications and is an international authority on molecular mechanisms of hormone action with more than 8400 citations and a h-factor of 56. Recent emphasis in his laboratory has focused on the capacity of specific secreted proteins to initiate or progress cancer and thereby evaluation of individual molecules for their potential therapeutic application. This latest focus has produced intellectual property of potential enormous utility and value.